SEATTLE--(BUSINESS WIRE)--Blaze Bioscience, Inc. announced today that Heather Franklin, Blaze’s President and CEO, will provide an introduction to Blaze Bioscience’s first Tumor Paint product, BLZ-100—currently in Phase 1 studies—as well as an overview of the company’s business strategy at 3:05 p.m. ET on Wednesday, August 13, 2014, at the 2014 Wedbush PacGrow Life Sciences Management Access Conference. The conference is being held in New York City. The presentation will be webcast.
Blaze Bioscience Presentation Details
|Date: Wednesday, August 13, 2014|
|Time: 3:05 p.m. EST|
|Location: Le Parker Meridien Hotel, New York|
About Blaze Bioscience
Blaze Bioscience is a clinical stage company dedicated to developing products that assist physicians in their quest to improve the lives of cancer patients. Blaze was co-founded by Dr. Jim Olson of Fred Hutchinson Cancer Research Center and Heather Franklin, a former senior business executive at ZymoGenetics, Inc. The company is developing Tumor Paint BLZ-100 for high-resolution, real-time visualization of cancer during surgery enabling better detection and more complete and precise removal of cancer. Blaze is collaborating with the Fred Hutchinson Cancer Research Center on a platform of Optide-based products with potential in imaging and therapeutic applications. For additional information, please visit www.blazebioscience.com.